Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA2 | Q9HCG7 | 7/20 | 0.43 |
| ▸ | GBA1 | P04062 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | UGCG | Q16739 | 2/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | AGL | P35573 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015303 | 0.91 | GBA1 (0.41) | GBA2GBA1BCHE | |
| SCHEMBL26050348 | 0.84 | GBA2 (0.47) | GBA2GBA1MEN1KMT2APOLB | |
| SCHEMBL4083015 | 0.77 | LMNA (0.33) | GBA2GBA1MEN1KMT2APOLB | |
| SCHEMBL9340416 | 0.76 | GBA2 (0.42) | GBA2GBA1MEN1KMT2APOLB | |
| SCHEMBL26050252 | 0.74 | GBA1 (0.45) | GBA2GBA1 | |
| SCHEMBL9863071 | 0.71 | GBA1 (0.48) | GBA2GBA1BCHEKCNH2 | |
| SCHEMBL5702265 | 0.71 | GBA2 (0.45) | GBA2GBA1MEN1KMT2APOLB | |
| SCHEMBL5701883 | 0.71 | GBA2 (0.45) | GBA2GBA1MEN1KMT2APOLB | |
| SCHEMBL4518775 | 0.70 | BCHE (0.37) | GBA2BCHEOPRD1KCNH2ALDH1A1 | |
| SCHEMBL27419314 | 0.69 | CYP3A4 (0.44) | GBA2GBA1POLBBCHECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3010488-A1 | STEREOSPECIFIC LIPIDS FOR LOCOREGIONAL THERAPY WITH LONG-TERM CIRCULATING STIMULI-SENSITIVE NANOCARRIER SYSTEMS | Thermosome Gmbh (DE) | 2016-04-27 | — | — | EP | claimed |
| WO-2014202680-A1 | STEREOSPECIFIC LIPIDS FOR LOCOREGIONAL THERAPY WITH LONG-TERM CIRCULATING STIMULI-SENSITIVE NANOCARRIER SYSTEMS | THERMOSOME GmbH (DE) | 2014-12-24 | — | — | WO | claimed |
| EP-3010488-A1 | STEREOSPECIFIC LIPIDS FOR LOCOREGIONAL THERAPY WITH LONG-TERM CIRCULATING STIMULI-SENSITIVE NANOCARRIER SYSTEMS | Thermosome Gmbh (DE) | 2016-04-27 | — | — | EP | disclosed |
| WO-2014202680-A1 | STEREOSPECIFIC LIPIDS FOR LOCOREGIONAL THERAPY WITH LONG-TERM CIRCULATING STIMULI-SENSITIVE NANOCARRIER SYSTEMS | THERMOSOME GmbH (DE) | 2014-12-24 | — | — | WO | disclosed |
| EP-1906987-A4 | METHODS AND COMPOSITIONS FOR EMERGENCY CONTRACEPTION USING ENDOTHELIN RECEPTOR ANTAGONISTS | POPULATION COUNCIL INC (US) | 2009-01-28 | — | — | EP | disclosed |
| US-7365093-B2 | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1906987-A1 | METHODS AND COMPOSITIONS FOR EMERGENCY CONTRACEPTION USING ENDOTHELIN RECEPTOR ANTAGONISTS | The Population Council, Inc. (US) | 2008-04-09 | — | — | EP | disclosed |
| US-7208517-B1 | Endothelin antagonists | ABBOTT LABORTORIES (US) | 2007-04-24 | — | — | US | disclosed |
| WO-2007012006-A1 | METHODS AND COMPOSITIONS FOR EMERGENCY CONTRACEPTION USING ENDOTHELIN RECEPTOR ANTAGONISTS | THE POPULATION COUNCIL, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20060229280-A1 | Endothelin antagonists | ABBVIE INC. | 2006-10-12 | — | — | US | disclosed |
| US-6946481-B1 | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2005-09-20 | — | — | US | disclosed |
| EP-1513852-A1 | PHOSPHATIDYL OLIGO GLYCERINS AND STRUCTURAL ANALOGS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003095464-A1 | PHOSPHATIDYL OLIGO GLYCERINS AND STRUCTURAL ANALOGS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2003-11-20 | — | — | WO | disclosed |
| US-6462194-B1 | Endothelin antagonists | ABBOTT LABORATORIES | 2002-10-08 | — | — | US | disclosed |
| US-6380241-B1 | FOR THERAPY OF CORONARY ANGINA, CEREBRAL VASOSPASM, ACUTE AND CHRONIC RENAL FAILURE, GASTRIC ULCERATION, CYCLOSPORIN-INDUCED NEPHROTOXICITY, ENDOTOXIN-INDUCED TOXICITY, ASTHMA, LPL-RELATED LIPOPROTEIN DISORDERS, PROLIFERATIVE DISEASES | ABBOTT LABORATORIES | 2002-04-30 | — | — | US | disclosed |
| WO-2002017912-A1 | ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | disclosed |
| US-6162927-A | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2000-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229280-A1 | Endothelin antagonists | EDNRA, EDNRB, ECE1 | GBA2 4044/4885GBA1 3358/4885MEN1 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.